Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml - vinca alkaloids and analogues

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; partially dehydrated liquid sorbitol; polysorbate 80; macrogol 400; titanium dioxide; purified water; iron oxide red - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.